Vanda Pharmaceuticals Inc VNDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VNDA is a good fit for your portfolio.
News
-
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
-
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
-
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
-
Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
-
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
-
Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
-
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
-
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $5.98
- Day Range
- $5.92–6.08
- 52-Week Range
- $3.31–6.76
- Bid/Ask
- $5.93 / $5.99
- Market Cap
- $346.28 Mil
- Volume/Avg
- 485,028 / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 76.11
- Price/Sales
- 1.94
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 203
- Website
- https://www.vandapharma.com
Comparables
Valuation
|
Metric
|
VNDA
|
EWTX
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 76.11 | — | — |
Price/Book Value | 0.64 | 2.98 | 1.56 |
Price/Sales | 1.94 | — | 2,719.83 |
Price/Cash Flow | 78.91 | — | — |
Price/Earnings
VNDA
EWTX
PLRX
Financial Strength
|
Metric
|
VNDA
|
EWTX
|
PLRX
|
|---|---|---|---|
Quick Ratio | 4.62 | 36.49 | 15.95 |
Current Ratio | 4.71 | 37.08 | 16.12 |
Interest Coverage | — | — | −138.69 |
Quick Ratio
VNDA
EWTX
PLRX
Profitability
|
Metric
|
VNDA
|
EWTX
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | 0.87% | −23.18% | −23.39% |
Return on Equity (Normalized) | 1.03% | −24.45% | −25.61% |
Return on Invested Capital (Normalized) | 1.02% | −28.92% | −29.08% |
Return on Assets
VNDA
EWTX
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Dymmmzzc | Lrdktf | $124.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jtgvbrshy | Tdzlq | $111.3 Bil | |||
| Moderna Inc
MRNA
| Mqmlvmqk | Pjmd | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Yrllrsqw | Glsr | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Wmvrxwph | Zbpps | $22.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wmbsctdx | Xyrvfg | $19.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pjzdlnn | Ddtjnsr | $15.3 Bil | |||
| Incyte Corp
INCY
| Rvjtzthp | Hfzfg | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Gchchpbgx | Xrvqcjk | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Gzjdzbc | Fpgy | $12.2 Bil |